AC Immune SA

NasdaqGM:ACIU Stock Report

Market Cap: US$257.4m

AC Immune Management

Management criteria checks 4/4

AC Immune's CEO is Andrea Pfeifer, appointed in Apr 2003, has a tenure of 7.92 years. total yearly compensation is CHF1.57M, comprised of 35.6% salary and 64.4% bonuses, including company stock and options. directly owns 2.58% of the company’s shares, worth $6.63M. The average tenure of the management team and the board of directors is 5.2 years and 6 years respectively.

Key information

Andrea Pfeifer

Chief executive officer

CHF1.6m

Total compensation

CEO salary percentage35.6%
CEO tenure21yrs
CEO ownership2.6%
Management average tenure5.2yrs
Board average tenure6yrs

Recent management updates

Recent updates

AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

Apr 05
AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Mar 15
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

Oct 06
Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth

We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Jun 03
We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth

Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

Nov 25
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

AC Immune Non-GAAP EPS of -$0.23 in-line

Jul 28

Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

Jul 06
Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation

AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

Feb 03
AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans

AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates

Jun 02

Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

May 09
Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?

AC Immune reports Q1 results; outlook

Apr 28

How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Feb 28
How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?

Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

Jan 24
Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts

We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

Jan 19
We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely

If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Dec 15
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%

Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues

AC Immune EPS misses by CHF0.02, beats on revenue

Nov 13

AC Immune and Wuxi Biologics boost development of TDP-43 antibodies

Nov 09

AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 30

CEO Compensation Analysis

How has Andrea Pfeifer's remuneration changed compared to AC Immune's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-CHF54m

Sep 30 2023n/an/a

-CHF68m

Jun 30 2023n/an/a

-CHF67m

Mar 31 2023n/an/a

-CHF69m

Dec 31 2022CHF2mCHF558k

-CHF71m

Sep 30 2022n/an/a

-CHF73m

Jun 30 2022n/an/a

-CHF76m

Mar 31 2022n/an/a

-CHF75m

Dec 31 2021CHF2mCHF530k

-CHF73m

Sep 30 2021n/an/a

-CHF71m

Jun 30 2021n/an/a

-CHF74m

Mar 31 2021n/an/a

-CHF71m

Dec 31 2020CHF2mCHF520k

-CHF62m

Sep 30 2020n/an/a

-CHF62m

Jun 30 2020n/an/a

-CHF25m

Mar 31 2020n/an/a

-CHF26m

Dec 31 2019CHF2mCHF510k

CHF45m

Sep 30 2019n/an/a

CHF50m

Jun 30 2019n/an/a

CHF18m

Mar 31 2019n/an/a

CHF24m

Dec 31 2018CHF2mCHF455k

-CHF51m

Sep 30 2018n/an/a

-CHF32m

Jun 30 2018n/an/a

-CHF27m

Mar 31 2018n/an/a

-CHF29m

Dec 31 2017CHF2mCHF404k

-CHF26m

Compensation vs Market: Andrea's total compensation ($USD1.72M) is about average for companies of similar size in the US market ($USD1.58M).

Compensation vs Earnings: Andrea's compensation has been consistent with company performance over the past year.

CEO

Andrea Pfeifer (66 yo)

21yrs

Tenure

CHF1,568,000

Compensation

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...

Leadership Team

NamePositionTenureCompensationOwnership
Andrea Pfeifer
Co-Founder21yrsCHF1.57m2.58%
CHF 6.6m
Christopher Roberts
CFO & VP of Finance2yrsno data0.013%
CHF 34.5k
Piergiorgio Donati
Chief Technical Operations Officer5.2yrsno data0.026%
CHF 67.2k
Jean-Fabien Monin
Chief Administrative Officer8.8yrsno data0.33%
CHF 854.7k
Howard Donovan
Chief HR Officer2yrsno data0.021%
CHF 55.2k
Madiha Derouazi
Chief Scientific Officerless than a yearno data0.0034%
CHF 8.7k
Gary Waanders
Senior VP of Investor Relations & Corporate Communicationsno datano datano data
Alexandre Caratsch
General Counselno datano datano data
Julian Snow
VP of U.S. Finance & Corporate Development2yrsno datano data
David Hickman
Head of AD - SME14.3yrsno datano data
Joseph Wettstein
Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer8.2yrsno datano data
Oliver Sol
VP & Head of Clinical Developmentno datano datano data

5.2yrs

Average Tenure

53.5yo

Average Age

Experienced Management: ACIU's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrea Pfeifer
Co-Founder7.9yrsCHF1.57m2.58%
CHF 6.6m
Jean-Marie Lehn
Chairman of Scientific Advisory Boardno datano datano data
Claude Nicolau
Member of Scientific Advisory Boardno datano datano data
Douglas Williams
Independent Non-Executive Chairman6yrsCHF194.00k0.041%
CHF 106.7k
Alf E. Lindberg
Member of Scientific Advisory Boardno datano datano data
Detlev Riesner
Member of Scientific Advisory Boardno dataCHF5.00kno data
Fred Van Leuven
Member of Scientific Advisory Boardno dataCHF105.00kno data
I. Rosenberg
Member of Scientific Advisory Boardno datano datano data
M. Monsigny
Member of Scientific Advisory Boardno datano datano data
E. Lestringant
Member of Scientific Advisory Boardno datano datano data
Monika Butler
Independent Vice Chair2.5yrsCHF208.00k0.0097%
CHF 25.1k
Andreas Monsch
Head of Clinical Advisory Boardno datano datano data

6.0yrs

Average Tenure

73.5yo

Average Age

Experienced Board: ACIU's board of directors are considered experienced (6 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.